FDA takes first step in possible reversal of ban on some peptides The Washington Post FDA's Overreach on Compounded Peptides Understanding the Legal Risks of BPC 157 and Other Unapproved Peptides Holt Law The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and clinics. With BPC 157, TB 500, and others under 503A review, questions around compounding, compliance, and what is BPC 157: Experimental Peptide Creates Risk for Athletes